Skip to main content
. 2020 Apr 29;21(9):3145. doi: 10.3390/ijms21093145

Figure 1.

Figure 1

Comparison of the effects of BJ-3105 and tofacitinib on AMPK activity and cytokine-induced adhesion of monocytic cells to colonic epithelial cells. (a,b) AMPK enzyme activity at an ATP concentration of 25 μM was measured using an in vitro enzyme assay kit (AMPK A1B1G1 kinase enzyme system) in the presence of different concentrations of AMP (a) or various concentrations of D942, VAS2870, tofacitinib, and BJ-3105 (b). Results are presented as the means ± SEMs of at least three independent experiments performed in triplicate. *p < 0.05, compared to the vehicle-treated control group. (c,d) Inhibitory effects of BJ-3105, tofacitinib, D-942, and AICAR on IL-6- (c) and on TNF-α-induced (d) U937 cell adhesion to HT-29 cells. BJ-3105, tofacitinib, D-942, and AICAR were pretreated for 1 h, and treated with TNF-α or IL-6 for 3 h. Results are presented as the means ± SEMs of at least three independent experiments. *p < 0.05, versus the vehicle-treated control group. #p < 0.05, versus the tofacitinib- or D942-treated group. (e) Cytotoxic effect of BJ-3105 and tofacitinib in CCD-841, a normal epithelial colon cell line. Cells were treated with BJ-3105 or tofacitinib for 48 h. *p < 0.05, versus the vehicle-treated control group.